Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 8/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939563 | 1.00 | CYP2C9 (0.36) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3938539 | 0.93 | RORC (0.36) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3938542 | 0.93 | RORC (0.36) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3935953 | 0.90 | CYP2C9 (0.38) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3944010 | 0.89 | CYP2C9 (0.37) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3929981 | 0.89 | POLB (0.39) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3934977 | 0.88 | CYP2C9 (0.37) | CYP2C9POLBKMT2AGAAMAPT | |
| SCHEMBL3930886 | 0.88 | CYP2C9 (0.36) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3940164 | 0.88 | POLB (0.37) | CYP2C9POLBRORCKMT2AGAA | |
| SCHEMBL3932107 | 0.87 | CYP2C9 (0.38) | CYP2C9POLBRORCKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| EP-2044059-A1 | 2,5-DISUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007141318-A1 | 2,5-DISUBSTITUTED PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | CYP2C9 619/4885POLB 2600/4885RORC 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.